SCHEMBL317765

SCHEMBL317765

O=C(ON1C(=O)CCC1=O)c1cccc(I)c1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPK1 P28482 1/20 0.43
KMT2A Q03164 3/20 0.40
MGLL Q99685 3/20 0.39
GRM5 P41594 1/20 0.38
SLC6A2 P23975 1/20 0.37
SLC6A4 P31645 1/20 0.37
SLC6A3 Q01959 1/20 0.37
UBE2D3 P61077 1/20 0.36
HDAC1 Q13547 1/20 0.35
HDAC2 Q92769 1/20 0.35
SIGMAR1 Q99720 1/20 0.34
ALDH1A1 P00352 2/20 0.34
CYP1A2 P05177 1/20 0.34
CYP3A4 P08684 1/20 0.34
CYP2D6 P10635 1/20 0.34
CYP2C9 P11712 1/20 0.34
HPGD P15428 1/20 0.34
CYP2C19 P33261 1/20 0.34
F2 P00734 1/20 0.34
TP53BP1 Q12888 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10261465 0.90 MAPK1 (0.39) MAPK1KMT2AMGLLGRM5SLC6A2
SCHEMBL14860981 0.89 MAPK1 (0.48) MAPK1KMT2AMGLLALDH1A1CYP1A2
SCHEMBL22076666 0.83 MGLL (0.33) MAPK1KMT2AMGLL
SCHEMBL4897945 0.83 CA12 (0.46) MAPK1KMT2AMGLLALDH1A1
SCHEMBL15305953 0.81 MAPK1 (0.43) MAPK1KMT2AMGLLALDH1A1CYP1A2
SCHEMBL317700 0.81 PLA2G7 (0.50) MAPK1KMT2AHDAC1ALDH1A1HPGD
SCHEMBL1284517 0.81 TSHR (0.48) MAPK1KMT2AALDH1A1
SCHEMBL13950373 0.81 MAPK1 (0.43) MAPK1KMT2AMGLLALDH1A1CYP1A2
SCHEMBL11595533 0.81 MAPK1 (0.43) MAPK1KMT2AMGLLALDH1A1CYP1A2
SCHEMBL1696190 0.81 NPC1 (0.47) MAPK1KMT2AALDH1A1HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 105 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2025046227-A1 X-RAY VISIBLE IMPLANTABLE SCAFFOLDS UCL BUSINESS LTD (GB) 2025-03-06 WO claimed
WO-2025046227-A1 X-RAY VISIBLE IMPLANTABLE SCAFFOLDS UCL BUSINESS LTD (GB) 2025-03-06 WO disclosed
US-12023389-B2 Compositions that target tumor-associated macrophages and methods of use therefor Sanford Burnham Prebys Medical Discovery Institute (US) 2024-07-02 US disclosed
EP-4379725-A2 IMMUNE RECOGNITION MOTIFS Iogenetics, LLC. (US) 2024-06-05 EP disclosed
US-20240131201-A1 COMPOSITIONS THAT TARGET TUMOR-ASSOCIATED MACROPHAGES AND METHODS OF USE THEREFOR Sanford Burnham Prebys Medical Discovery Institute 2024-04-25 US disclosed
WO-2024023332-A1 SILICON-BASED FLUORIDE ACCEPTOR GROUPS FOR RADIOPHARMACEUTICALS Technische Universität München (DE) 2024-02-01 WO disclosed
EP-3167396-B1 IMMUNE RECOGNITION MOTIFS IOGENETICS LLC (US) 2024-01-17 EP disclosed
EP-4185336-A1 SILICON-CONTAINING LIGAND COMPOUNDS Technische Universität München (DE) 2023-05-31 EP disclosed
US-11571484-B2 Compositions that target tumor-associated macrophages and methods of use therefor Sanford Burnham Prebys Medical Discovery Institute (US) 2023-02-07 US disclosed
US-20220348681-A1 FUSED PROTEIN OF AN ANTIBODY WHICH RECOGNIZES CANCER-CELLS AND A STREPTAVIDIN MUTANT THE UNIVERSITY OF TOKYO (JP) 2022-11-03 US disclosed
WO-2009138763-A1 FORMATION OF 18F AND 19F FLUOROARENES BEARING REACTIVE FUNCTIONALITIES UNIVERSITY OF NEWCASTLE UPON TYNE (GB) 2009-11-19 WO disclosed
WO-2009138763-A1 FORMATION OF 18F AND 19F FLUOROARENES BEARING REACTIVE FUNCTIONALITIES UNIVERSITY OF NEWCASTLE UPON TYNE (GB) 2009-11-19 WO disclosed
US-20090286992-A1 FORMATION OF 18F AND 19F FLUOROARENES BEARING REACTIVE FUNCTIONALITIES UNIVERSITY OF NEWCASTLE UPON TYNE (GB) 2009-11-19 US disclosed
US-20090005545-A1 METHODS FOR PURIFYING RADIOLABELLED COMPOUNDS MCMASTER UNIVERSITY 2009-01-01 US disclosed
US-7335347-B2 Methods for purifying radiolabelled compounds MCMASTER UNIVERSITY (CA) 2008-02-26 US disclosed
EP-1135170-B1 RADIOCONJUGATION OF INTERNALIZING ANTIBODIES UNIV DUKE (US) 2006-10-25 EP disclosed
US-6998106-B1 Radioconjugation of internalizing antibodies DUKE UNIVERSITY (US) 2006-02-14 US disclosed
US-6426400-B1 COMPLEXES DUKE UNIVERSITY 2002-07-30 US disclosed
EP-1135170-A2 RADIOCONJUGATION OF INTERNALIZING ANTIBODIES DUKE UNIVERSITY (US) 2001-09-26 EP disclosed
WO-2000032240-A2 RADIOCONJUGATION OF INTERNALIZING ANTIBODIES DUKE UNIVERSITY (US) 2000-06-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090286992-A1 FORMATION OF 18F AND 19F FLUOROARENES BEARING REACTIVE FUNCTIONALITIES RARB, RARG, RARA MAPK1 1701/4885KMT2A 1417/4885MGLL 4447/4885
US-20220348681-A1 FUSED PROTEIN OF AN ANTIBODY WHICH RECOGNIZES CANCER-CELLS AND A STREPTAVIDIN MUTANT SPEN, IGSF11, MYCBP MAPK1 3555/4885KMT2A 1440/4885MGLL 4746/4885
US-20090005545-A1 METHODS FOR PURIFYING RADIOLABELLED COMPOUNDS PAICS, PFAS, NPEPPS MAPK1 4277/4885KMT2A 2099/4885MGLL 411/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.